Holen Sie sich die Stockscreener-App
17.01
3.13%
-0.55
Handel nachbörslich:
17.04
0.03
+0.18%
Schlusskurs vom Vortag:
$17.56
Offen:
$17.6
24-Stunden-Volumen:
680.36K
Relative Volume:
0.61
Marktkapitalisierung:
$1.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-230.32M
KGV:
-4.8243
EPS:
-3.5259
Netto-Cashflow:
$-196.04M
1W Leistung:
+2.10%
1M Leistung:
-2.02%
6M Leistung:
+60.62%
1J Leistung:
-59.41%
1-Tages-Spanne:
$16.97
$18.00
1-Wochen-Bereich:
$16.01
$18.00
52-Wochen-Spanne:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
17.01 | 1.28B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Hochstufung | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | Herabstufung | Goldman | Neutral → Sell |
| 2026-01-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-11-03 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-09-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-09-30 | Herabstufung | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Herabstufung | Stifel | Buy → Hold |
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
Responsive Playbooks and the MLTX Inflection - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Short Interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) Decreases By 14.2% - MarketBeat
MLTX Price Today: MoonLake Immunotherapeutics Stock Price, Quote & Chart | MEXC - MEXC Exchange
MoonLake plunges after mixed results from skin disease trial - MSN
MoonLake Immunotherapeutics (MLTX) Proxy Filing Summary - Quartr
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
Moonlake surges as no additional studies are required for lead drug - MSN
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Why Is MoonLake Immunotherapeutics Stock Crashing Premarket? - MSN
Understanding the Setup: (MLTX) and Scalable Risk - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ: MLTX) puts 6.2% equity plan dilution to shareholder vote - Stock Titan
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? - AOL.com
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? - The Motley Fool
Have Insiders Sold MoonLake Immunotherapeutics Shares Recently? - Sahm
Insider Sell: Matthias Bodenstedt Sells Shares of MoonLake Immun - GuruFocus
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - AOL.com
MoonLake (MLTX) CFO sells 2,426 shares under Rule 10b5-1 plan - Stock Titan
H.C. Wainwright reiterates Moonlake stock rating on HS potential By Investing.com - Investing.com Australia
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
H.C. Wainwright reiterates Moonlake stock rating on HS potential - Investing.com
Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention - TipRanks
Insider Sell: CEO Santos da Silva Jorge Sells 150,000 Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 51,873 Shares - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 98,127 Shares - MarketBeat
MoonLake Immunotherapeutics Chief Executive Officer Sold Shares Worth Over $2.7M - TradingView — Track All Markets
MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares - Stock Titan
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics - TipRanks
MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal
The Technical Signals Behind (MLTX) That Institutions Follow - Stock Traders Daily
Pre-planned MoonLake (NASDAQ: MLTX) CFO share sale totals 87,795 - Stock Titan
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):